Feb 8 |
Citi starts Cogent Biosciences at buy, cites GI tumor drug potential
|
Feb 8 |
AIM stock dips amid mixed results for post-COVID fatigue therapy
|
Feb 5 |
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
|
Jan 9 |
Cogent Biosciences issues study updates on bezuclastinib, CGT4859
|
Jan 9 |
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
|
Jan 2 |
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 11 |
Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment
|
Dec 11 |
Cogent slumps after mid-stage data for rare disorder therapy
|
Dec 11 |
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
|
Dec 9 |
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
|